8/6/2009

GlaxoSmithKline agreed to pay Vernalis as much as $200 million, including $6 million upfront, in relation to the biotech firm's cancer research. GSK will oversee preclinical development of compounds from studies and also have an option to license any of those treatments.

Related Summaries